Incyte Q1 Results Top Estimates

RTTNews | 1184 days ago
Incyte Q1 Results Top Estimates

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $161.43 million or $0.72 per share for the first quarter, up from $149.46 million or $0.67 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter was $1.01 per share, compared to $0.80 per share in the year-ago quarter.

Total revenues for the quarter rose 29 percent to $911.40 million from $705.71 million in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.76 per share on revenues of $818.49 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2022, Incyte now projects Jakafi net product revenue in a range of $2.36 billion to $2.40 billion. Other Hematology/Oncology net product revenues are projected between $210 million and $240 million.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.
RTTNews | 624 days ago
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD).
RTTNews | 950 days ago
Australian Market Trims Early Losses In Mid-market

Australian Market Trims Early Losses In Mid-market

The Australian market is trimming its early losses in mid-market moves on Thursday, but adding to the losses in the previous two sessions, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling to near the 8,900 level, with gains in iron ore miners and financial stocks partially offset by weakness in technology stocks.
RTTNews | 41 minutes ago
Asian Markets Trade Mostly Higher

Asian Markets Trade Mostly Higher

Asian markets are trading mostly higher on Thursday, following the mixed cues from Wall Street overnight, amid optimism about a potential trade deal between the U.S. and China as US President Donald Trump and Chinese President Xi Jinping meet. Traders also react to another quarter point interest rate cut by the US Fed. Asian markets closed mostly higher on Wednesday.
RTTNews | 56 minutes ago
Japanese Market Modestly Lower

Japanese Market Modestly Lower

The Japanese market is modestly lower in choppy trading on Thursday, reversing some of the sharp gains in the previous session, following the mixed cues from Wall Street overnight. The Nikkei 225 is falling well below the 51,150 level, with weakness in index heavyweights and automaker stocks partially offset by gains in financial and technology stocks.
RTTNews | 2h 40min ago
China Bourse May Slip Beneath 4,000-Point Level

China Bourse May Slip Beneath 4,000-Point Level

The China stock market bounced higher again on Wednesday, one day after ending the three-day winning streak in which it had collected more than 80 points or 2 percent. The Shanghai Composite Index now sits just above the 4,015-point plateau although it may head south again on Thursday.
RTTNews | 3h 3min ago
Australian Market Modestly Lower

Australian Market Modestly Lower

The Australian market is trading modestly lower on Thursday, adding to the losses in the previous two sessions, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling below the 8,900 level, with gains in iron ore miners and financial partially offset by weakness in technology stocks.
RTTNews | 3h 11min ago